Massachusetts Financial Services Co. MA Purchases 16,012 Shares of Hologic, Inc. (NASDAQ:HOLX)

Massachusetts Financial Services Co. MA lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 56.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 44,291 shares of the medical equipment provider’s stock after acquiring an additional 16,012 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Hologic were worth $3,193,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Brooklyn Investment Group raised its stake in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 145 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. UMB Bank n.a. grew its position in Hologic by 4.1% in the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 188 shares during the last quarter. Finally, Capital Investment Counsel Inc grew its holdings in shares of Hologic by 3.6% during the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock valued at $413,000 after purchasing an additional 200 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Wolfe Research initiated coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. Morgan Stanley reduced their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Raymond James reiterated an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Citigroup dropped their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Performance

HOLX opened at $61.27 on Tuesday. Hologic, Inc. has a 12-month low of $59.06 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $13.75 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.14 and a beta of 0.82. The company’s 50 day moving average is $64.07 and its 200 day moving average is $72.37.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.